Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Benjamin Tran

Dermatology Pasadena, CA Medical Doctor

NPI 1386263317 CMS profile 11554236

625 S Fair Oaks Ave Ste 200, Pasadena, CA 91105

Open in the dashboard

General payments

$5,564

176 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Tran of Pasadena, CA is reported in the CMS Open Payments database as having received $5,564 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,786 134
2024 General $1,747 41
2023 General $31 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Tran
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Benjamin Tran were reported at $3,786. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Benjamin Tran Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $31 $607 $159–$1,674 $160
2024 $1,747 $751 $204–$1,903 $164
2025 $3,786 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,270 48 payments
  2. Genzyme Corporation $864 23 payments
  3. Regeneron Healthcare Solutions, Inc. $507 11 payments
  4. UCB, Inc. $499 10 payments
  5. Arcutis Biotherapeutics, Inc. $378 22 payments
  6. Incyte Corporation $300 14 payments
  7. LEO Pharma Inc. $224 10 payments
  8. Revance Therapeutics, Inc. $211 2 payments
  9. Janssen Biotech, Inc. $202 2 payments
  10. Botanix SB Inc $160 4 payments
  11. Other $948 30 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,378 173 payments
  2. Education $167 2 payments
  3. Travel and Lodging $20 1 payment
Products named General payments · program years 2023–2025
  1. DUPIXENT Immunology $959 24 payments
  2. BOTOX $564 28 payments
  3. Bimzelx $499 10 payments
  4. Zoryve $378 22 payments
  5. OPZELURA $300 14 payments
  6. VTAMA $280 3 payments
  7. DUPIXENT Immunology And Inflammation $253 7 payments
  8. DUPIXENT Inflammation And Immunology $223 3 payments
  9. UBRELVY $213 10 payments
  10. DAXXIFY $211 2 payments
  11. Other $1,808 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

92

Median for Dermatology: 534

Drug cost

$3,547

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tacrolimus Generic 12 $1,003
Clindamycin Phosphate Generic 20 $936
Fluorouracil Generic 11 $814
Triamcinolone Acetonide Generic 23 $351
Ketoconazole Generic 13 $261
Hydrocortisone Generic 13 $182

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$11,384

Medicare's payments for the services billed

Medicare patients

65

Average age 76

Services billed

1,247

26 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 34%
Atrial fibrillation 31%
Diabetes 26%
Heart failure 26%
Chronic kidney disease 23%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $223
  • GENZYME CORPORATION $223
$445 — —
Bimzelx
  • UCB, Inc. $311
$311 — —
BOTOX
  • AbbVie, Inc. $265
$265 — —
TREMFYA
  • Janssen Biotech, Inc. $202
$202 — —
VTAMA
  • Dermavant Sciences, Inc. $148
$148 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record